{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:08:30Z","timestamp":1783922910836,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ferring Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10620-025-09629-0","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:25:33Z","timestamp":1766517933000},"page":"2218-2228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ten-Year Trend in 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients with Ulcerative Colitis: An Analysis of Korean Health Insurance Data"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-6809","authenticated-orcid":false,"given":"Soo Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4237-520X","authenticated-orcid":false,"given":"Sang Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-8904","authenticated-orcid":false,"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"9629_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","volume":"21","author":"JP Segal","year":"2021","unstructured":"Segal JP, LeBlanc J-F, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135\u2013139. https:\/\/doi.org\/10.7861\/clinmed.2021-0080.","journal-title":"Clin Med (Lond)"},{"key":"9629_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","volume":"49","author":"L Du","year":"2020","unstructured":"Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin N Am 2020;49:643\u2013654. https:\/\/doi.org\/10.1016\/j.gtc.2020.07.005.","journal-title":"Gastroenterol Clin N Am"},{"key":"9629_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet 2023;402:571\u2013584. https:\/\/doi.org\/10.1016\/S0140-6736(23)00966-2.","journal-title":"Lancet"},{"key":"9629_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s10620-017-4640-9","volume":"62","author":"YS Jung","year":"2017","unstructured":"Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and clinical outcomes of inflammatory Bowel disease in South Korea, 2011\u20132014: A Nationwide Population-Based Study. Dig Dis Sci 2017;62:2102\u20132112. https:\/\/doi.org\/10.1007\/s10620-017-4640-9.","journal-title":"Dig Dis Sci"},{"key":"9629_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3349\/ymj.2021.62.2.99","volume":"62","author":"J Park","year":"2021","unstructured":"Park J, Cheon JH. Incidence and prevalence of inflammatory Bowel disease across Asia. Yonsei Med J 2021;62:99\u2013108. https:\/\/doi.org\/10.3349\/ymj.2021.62.2.99.","journal-title":"Yonsei Med J"},{"key":"9629_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3904\/kjim.2022.138","volume":"37","author":"JW Lee","year":"2022","unstructured":"Lee JW, Eun CS. Inflammatory bowel disease in Korea: epidemiology and pathophysiology. Korean J Intern Med 2022;37:885\u2013894. https:\/\/doi.org\/10.3904\/kjim.2022.138.","journal-title":"Korean J Intern Med"},{"key":"9629_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5217\/ir.2021.00115","volume":"20","author":"SH Park","year":"2022","unstructured":"Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now? Intest Res 2022;20:159\u2013164. https:\/\/doi.org\/10.5217\/ir.2021.00115.","journal-title":"Intest Res"},{"key":"9629_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","volume":"18","author":"C Le Berre","year":"2020","unstructured":"Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and crohn\u2019s disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol 2020;18:14\u201323. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.005.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9629_CR9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet 2017;389:1756\u20131770. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"Lancet"},{"key":"9629_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-med-052919-120048","volume":"72","author":"RP Hirten","year":"2021","unstructured":"Hirten RP, Sands BE. New Therapeutics for Ulcerative Colitis. Annu Rev Med 2021;72:199\u2013213. https:\/\/doi.org\/10.1146\/annurev-med-052919-120048.","journal-title":"Annu Rev Med"},{"key":"9629_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S2468-1253(18)30231-0","volume":"3","author":"NH Nguyen","year":"2018","unstructured":"Nguyen NH, Fumery M, Dulai PS et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742\u2013753. https:\/\/doi.org\/10.1016\/S2468-1253(18)30231-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9629_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/ecco-jcc\/jjab010","volume":"15","author":"B Barberio","year":"2021","unstructured":"Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis 2021;15:1184\u20131196. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab010.","journal-title":"J Crohns Colitis"},{"key":"9629_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5217\/ir.2017.15.1.7","volume":"15","author":"CH Choi","year":"2017","unstructured":"Choi CH, Moon W, Kim YS et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res 2017;15:7\u201337. https:\/\/doi.org\/10.5217\/ir.2017.15.1.7.","journal-title":"Intest Res"},{"key":"9629_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","volume":"156","author":"CW Ko","year":"2019","unstructured":"Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019;156:748\u2013764. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.009.","journal-title":"Gastroenterology"},{"key":"9629_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5217\/ir.2012.10.1.1","volume":"10","author":"CH Choi","year":"2012","unstructured":"Choi CH, Kim Y-H, Kim YS et al. Guidelines for the management of ulcerative colitis. Intest Res 2012;10:1\u201325. https:\/\/doi.org\/10.5217\/ir.2012.10.1.1.","journal-title":"Intest Res"},{"key":"9629_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis Part 2: Current Management. J Crohns Colitis 2017;11:769\u2013784. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009.","journal-title":"J Crohns Colitis"},{"key":"9629_CR17","first-page":"CD000543","volume":"4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;4:CD000543.","journal-title":"Cochrane Database Syst Rev"},{"key":"9629_CR18","first-page":"CD000544","volume":"2016","author":"Y Wang","year":"2016","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;2016:CD000544.","journal-title":"Cochrane Database Syst Rev"},{"key":"9629_CR19","first-page":"CD000544","volume":"8","author":"A Murray","year":"2020","unstructured":"Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000544.","journal-title":"Cochrane Database Syst Rev"},{"key":"9629_CR20","first-page":"CD000543","volume":"8","author":"A Murray","year":"2020","unstructured":"Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543.","journal-title":"Cochrane Database Syst Rev"},{"key":"9629_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.24304\/kjcp.2020.30.2.102","volume":"30","author":"J Kim","year":"2020","unstructured":"Kim J, Park S-H, Shin J-Y. Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database. Korean J Clin Pharm 2020;30:102\u2013112. https:\/\/doi.org\/10.24304\/kjcp.2020.30.2.102.","journal-title":"Korean J Clin Pharm"},{"key":"9629_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"9629_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","volume":"20","author":"C Le Berre","year":"2020","unstructured":"Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther 2020;20:363\u2013378. https:\/\/doi.org\/10.1080\/14712598.2019.1666101.","journal-title":"Expert Opin Biol Ther"},{"key":"9629_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5217\/ir.2023.00061","volume":"21","author":"J Park","year":"2023","unstructured":"Park J. How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries? Intest Res 2023;21:275\u2013276. https:\/\/doi.org\/10.5217\/ir.2023.00061.","journal-title":"Intest Res"},{"key":"9629_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5217\/ir.2022.00006","volume":"21","author":"JH Cheon","year":"2023","unstructured":"Cheon JH, Paridaens K, Awadhi SA et al. The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intest Res 2023;21:161\u2013167. https:\/\/doi.org\/10.5217\/ir.2022.00006.","journal-title":"Intest Res"},{"key":"9629_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5217\/ir.2022.00007","volume":"21","author":"S-Y Na","year":"2022","unstructured":"Na S-Y, Choi CH, Song EM et al. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res 2022;21:61\u201387. https:\/\/doi.org\/10.5217\/ir.2022.00007.","journal-title":"Intest Res"},{"key":"9629_CR27","unstructured":"Korean Association for the Study of Intestinal Diseases,. 2020 Inflammatory bowel disease fact sheet in Korea. Seoul: Korean Association for the Study of Intestinal Diseases;2020."},{"key":"9629_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000543","author":"L Sutherland","year":"2003","unstructured":"Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003. https:\/\/doi.org\/10.1002\/14651858.CD000543.","journal-title":"Cochrane Database Syst Rev"},{"key":"9629_CR29","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.3748\/wjg.15.4353","volume":"15","author":"C Prantera","year":"2009","unstructured":"Prantera C, Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009;15:4353\u20134355. https:\/\/doi.org\/10.3748\/wjg.15.4353.","journal-title":"World J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09629-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:30:20Z","timestamp":1783920620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09629-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["9629"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09629-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SJP declares no conflict of interest. JHC is an editorial board member of\n                      Digestive Diseases and Sciences.\n                      SWP is a full-time employee of Ferring Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of the Severance Hospital of the Yonsei University Health System (Approval Number 4-2020-0234). Patients\u2019 informed consent was waived based on the retrospective design of the study and the use of anonymous data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}